Quarterly ResultAug 13, 2026, 05:18 PM
Telomir Q2 Net Loss $1.72M; Cash $5.17M; Going Concern Warning
AI Summary
Telomir Pharmaceuticals reported a net loss of $(1,721,528) for the three months ended June 30, 2026, and $(2,712,475) for the six months. The company's cash balance decreased to $5.17 million by June 30, 2026, from $7.29 million at the end of 2025, with $2.79 million used in operations during the first half of 2026. Management issued a going concern warning, indicating insufficient cash to fund operations for the next 12 months. Additionally, Telomir completed its merger with related party TELI Pharmaceuticals, Inc. on April 22, 2026, acquiring global rights to Telomir-Zn.
Key Highlights
- Net loss for the three months ended June 30, 2026, was $(1,721,528).
- Net loss for the six months ended June 30, 2026, was $(2,712,475).
- Cash balance stood at $5,170,286 as of June 30, 2026.
- Cash used in operating activities for H1 2026 totaled $(2,785,842).
- Company issued a going concern warning for the next 12 months.
- Completed merger with TELI Pharmaceuticals, Inc. on April 22, 2026.
- Issued 34,389,710 common shares for TELI acquisition, valued at $47,113,903.
- Research and development expenses for H1 2026 increased to $912,471.
Price Impact
More from TELO